Concomitant Immune Check Point Inhibitor With Radiochemotherapy in Head And Neck Cancer

NCT03532737 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Locally Advanced Head and Neck Cancer

Interventions

DRUG: Pembrolizumab

Sponsor

Kuwait Cancer Control Center